Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: A system and method for calibrating an image acquisition device are provided. First characteristic information of one or more optical markers in a first coordinate system applied to a medical device may be obtained. Multiple images each of which includes the one or more optical markers acquired by an image acquisition device may be obtained. Second characteristic information of the one or more optical markers in a second coordinate system applied to the multiple images acquired by the image acquisition device based on the multiple images may be obtained. A transform relationship between the first coordinate system and the second coordinate system may be determined based on the first characteristic information and the second characteristic information of the one or more optical markers.

Abstract: The present invention relates to the combination of Bcl-2 inhibitor Compound (A) in combination with a chemotherapeutic agent Compound (B) selected from azacitidine, bendamustine, bortezomib, carfilzomib, ixazomib, busulfan, carboplatin, cytarabine, cyclophosphamide, cladribine, cisplatin, capecitabine, decitabine, etoposide, fludarabine, gemcitabine, daunorubicin, doxorubicin, ifosfamide, methotrexate and vincristine, or a pharmaceutically acceptable salt of any of the foregoing, for the treatment of a disease or condition in particular hematological cancers.

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: The salt, such as adipate salt Form A, and freebase forms of Compound A are WEE inhibitors. Such salts and/or forms and freebase forms, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.

Abstract: A process is provided for making a WEE1 inhibitor of the formula (1A) useful in the treatment of conditions characterized by excessive cellular proliferation, such as cancer. In some embodiments, processes are provided for making intermediate compounds of the formulae (3), (5) and (6) as defined herein.

Abstract: Disclosed herein are compounds of Formula (A) as defined herein, and combinations of compounds, for treating amylodosis. Some of the types of amyloidosis that are treated include amyloid light-chain (AL) amyloidosis, amyloid type A (AA) amyloidosis, dialysis-related amyloidosis (DRA), familial or hereditary amyloidosis, age-related (senile) systemic amyloidosis, and organ-specific amyloidosis. In various embodiments, a compound of the Formula (A) is used in combination with a corticosteroid for the treatment of amyloidosis.

Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

Abstract: Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.

Abstract: The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by excessive cellular proliferation such as cancer.

Abstract: Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein.

Abstract: Disclosed herein are combination therapies of Bcl-2 inhibitors (Compound (A), along with pharmaceutically acceptable salts thereof) and CDK 4/6 inhibitors (Compound (B), along with pharmaceutically acceptable salts thereof) for treating a disease or condition, such as a cancer, including breast cancer and leukemia.

Abstract: The present application is related to an improved process for synthesising 1-(difluoromethyl)-3-iodobicyclo[1.1.1]pentane from difluoromethyl iodide and [1.1.1]propellane. Difluoromethyl iodide is made by reacting an iodide salt with chlorodifluoroacetic acid in the presence of a solvent such as sulfolane and an inorganic base, [1.1.1]propellane is synthesised by reacting 1,1-dibromo-2,2-cis(chloromethyl)cyclopropane with a reagent such as magnesium, methyllithium or phenyllithium.

Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Disclosed are a projection device and a spatial imaging method. The projection device includes: an optical fiber scanner array; a light source located on an incident light path of the optical fiber scanner array; and an adjustment and control module assembly configured to couple, according to a virtual scene to be displayed, light emitted by the light source into the optical fiber scanner array, and to control the optical fiber scanner array to project pencil beams to a plurality of virtual object points corresponding to the virtual scene and located in space, such that multiple pencil beams projected to each virtual object point form a bundle of emitting light beams.